Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouragi... ( SEATTLE Aug. 22 /- Vical Incorpor...)

Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results

Date:8/22/2007

SEATTLE, Aug. 22 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) announced today that results from a series of HIV vaccine Phase 2a clinical trials, using a plasmid DNA (pDNA) vaccine developed by the NIH Vaccine Research Center and manufactured by Vical, reinforced previously reported Phase 1 conclusions that a "DNA prime-adenoviral vector boost" vaccine regimen was safe and well-tolerated, and was effective in inducing T-cell immune responses in up to 70% of the vaccine recipients.

"These recent vaccine trials contribute to the growing body of knowledge demonstrating plasmid DNA priming as a key factor in achieving significant immune responses against HIV, a particularly difficult target pathogen, bringing us one step closer to evaluating the effectiveness of a prime-boost HIV vaccine regimen in a prophylactic setting," said Vijay B. Samant, Vical's President and Chief Executive Officer. "The latest International AIDS Vaccine Initiative (IAVI) listing of ongoing preventive HIV vaccine clinical trials shows that more than half use pDNA either alone or in combination with other vaccine modalities. We are very pleased that DNA technology is an integral part of the effort to address this high priority global health problem."

The trials involved priming an immune response with three doses of a pDNA vaccine over a two month period, based on Vical's proprietary DNA technology, and boosting the response with a single dose of adenoviral vector vaccine at six months. The three trials, collectively known as TRIAD, were conducted by the National Institute of Allergy and Infectious Diseases (NIAID) HIV Trials Vaccine Network (HVTN), the IAVI, and the U.S. Military HIV Research Program (USMHRP). Richard Koup, M.D., Chief of Immunology at the Dale and Betty Bumpers Vaccine Research Center (VRC), NIAID, National Institutes of Health (NIH), highlighted TRIAD summary results and conclusions in an oral presentation, "Update on safety and immunogenicity
'/>"/>

SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis

Post Your Comments:

(Date:5/21/2013)... 21, 2013 Lakeland Industries, Inc. (NASDAQ: ... industrial protective clothing for industry, municipalities, healthcare and ... levels, today announced that the Company accepted a ... Credit Facility subject to certain terms and conditions ... However, no assurances can be given that this ...

(Date:5/21/2013)... May 21, 2013 Regulus Therapeutics Inc . ... discovery and development of innovative medicines targeting microRNAs, today ... Ph.D., Chief Operating Officer and Executive Vice President, Finance, ... 38th Annual Healthcare Conference on Wednesday, May 29, 2013 ... at the Westin Boston Waterfront Hotel. The ...

(Date:5/21/2013)... , May 21, 2013 Tom Daulton, CEO of Mammotome, ... of the Year by the Cincinnati ... was nominated by another local top executive who is also ... brand from Ethicon Endo-Surgery in March of 2010. Daulton will ... Awards program, presented by Huntington Bank, on May 22. ...

[0] Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results [0] Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference [0] Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year

... - VASTox plc (AIM: VOX), a leading,UK biotechnology ... of £400,000 by the Welsh Development Agency,(”WDA”) under ... 12 months, will support the research and development,work ... the unique skills and expertise of its scientists,based ...

... 2007 /PRNewswire-USNewswire/ -- The,following statement may be attributed ... Medical Research (CAMR): , "In the face of ... the stroke of his veto pen deliberately to ... well as endanger,the future health and well being ...

Cached Medicine Technology:Vastox Awarded £400,000 Grant to Support R&D at,Carbohydrate Chemistry Facility 2 Vastox Awarded £400,000 Grant to Support R&D at,Carbohydrate Chemistry Facility 3 President Bush Ignores America's Plea for Support of Stem Cell,Research 2

Vastox Awarded £400,000 Grant to Support R&D at,Carbohydrate Chemistry Facility President Bush Ignores America's Plea for Support of Stem Cell,Research

(Date:5/21/2013)... May 22, 2013 Feed additives have ... production industry value chain. Most of the feed additives ... injectable, pellets, liquids, and powders. There are variety of ... and concentrations depending upon the type of animal and ... vitamins that provide essential nutrition to the animal in ...

(Date:5/21/2013)... (PRWEB) May 21, 2013 Medical Ministry ... the prestigious 2013 Top-Rated Award by GreatNonprofits , the ... are excited to be named a Top-Rated 2013 Nonprofit,” says ... the dedication of our over 3000 Volunteers and Staff serving ... significant as it came from those that have seen our ...

(Date:5/21/2013)... on a large scale is the cornerstone of ... better outcomes, better value and better experience of ... patient-centered medical home model offers a viable solution ... of Health and Human Services, Agency for Healthcare ... more about the processes and determinants of successful ...

(Date:5/21/2013)... 21, 2013 Mecklenburg EMS Agency (Medic) ... hold a free Community Wellness Fair to educate the public ... will be held on Wednesday, May 22, 2013 from 4:00 ... (8100 Old Mallard Creek Road, Charlotte, NC 29262). ... and the Mecklenburg County Department of Social Services ...

(Date:5/21/2013)... May 2013, Paris, France: The Orsiro stent, which ... a biodegradable polymer, demonstrated non-inferiority to the Xience ... of in-stent late lumen loss at nine months ... at EuroPCR 2013 today. , The BIOFLOW-II substudy ... (OCT) to quantitatively assess neointimal hyperplasia and stent ...

Breaking Medicine News(10 mins):Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 2 Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 3 Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 4 Health News:Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org 2 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6 Health News:Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives 2 Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2

[0] Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com [0] Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org [0] AHRQ-funded journal supplement offers lessons on primary care practice transformation [0] Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives [0] Biodegradable stent proves non-inferior to drug-eluting stent

... 12 The Female Health Company (NYSE Alternext: ... (FDA) Obstetrics and Gynecology Devices Advisory Committee has unanimously voted ... is approvable with a single condition. , ... the product is approvable with the condition that the FC2 ...

... HOUSTON, Dec. 12 Access MediQuip, LLC, ... medical implantable device management,solutions to the healthcare ... industry,s first national contract for device benefit ... with WellPoint, Inc. to deliver,implantable device management ...

... and only approved peginterferon in combination with ribavirin for ... medical need , , ... SGP ) today announced that the U.S. Food ... PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy ...

... director for the Pew Campaign on Human Health and ... U.S. Food and Drug Administration,s decision to reverse its ... animal agriculture: , , ... the increase in antibiotic-resistant infections - a fact long ...

... Hospitals Case Medical Center in conjunction with Sodexo Health Care ... Nosh 24/6 unit, the original certified kosher hot food vending ... machine in the state of Ohio, offering patients and their ... , , University Hospitals prides ...

... Life Insurance,Company (John Hancock) is reinforcing its commitment ... training requirements through an,affiliation with the ClearCert Clearinghouse. ... in the year and effective January 1, 2009,will ... , Since ...

Cached Medicine News:Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 2 Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 3 Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 4 Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 5 Health News:Access MediQuip and WellPoint Finalize First National Contract for Implantable Medical Devices 2 Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 2 Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 3 Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 4 Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 5 Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 6 Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 7 Health News:Statement From The Pew Charitable Trusts on the U.S. Food and Drug Administration's Reversal on Antibiotics Safeguards in Animal Farming 2 Health News:University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine 2 Health News:University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine 3 Health News:John Hancock Expands LTC Training Effort with ClearCert High Usage By Producers and Streamlines Process for Insurers 2 Health News:John Hancock Expands LTC Training Effort with ClearCert High Usage By Producers and Streamlines Process for Insurers 3

FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable Access MediQuip and WellPoint Finalize First National Contract for Implantable Medical Devices Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C Statement From The Pew Charitable Trusts on the U.S. Food and Drug Administration's Reversal on Antibiotics Safeguards in Animal Farming University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine John Hancock Expands LTC Training Effort with ClearCert High Usage By Producers and Streamlines Process for Insurers

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

Medicine Products:

Dapsone, Serum or Plasma Dalmane D-lysergic Acid Diethylamide, Urine D, 1-25 Dihydroxy, Vitamin